Leukeran (Chlorambucil)

Chlorambucil alkylates DNA, forming cross‑links that prevent DNA strands from separating during replication and transcription. This interference leads to cell cycle arrest and ultimately triggers apoptosis of rapidly dividing malignant cells, especially lymphocytes.

The dosage of Leukeran is individualized by the prescribing clinician based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and other clinical factors. The prescriber determines the appropriate dose and schedule.

The safety of chlorambucil in pregnancy and lactation is not well established. It is generally avoided because it can cross the placenta and be excreted in breast milk, potentially harming the fetus or infant. Consultation with a healthcare professional is essential before use.

To request Leukeran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, offering convenience over intravenous drugs like cyclophosphamide. While effective for certain hematologic malignancies, it may have a different toxicity profile, with notable bone‑marrow suppression. Choice of therapy depends on disease characteristics, patient tolerance, and treatment goals.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

Leukeran is taken orally, usually with water. The exact dosing schedule—such as daily, weekly, or cyclic administration—is determined by the treating physician based on the individual treatment plan.

Serious risks include severe bone‑marrow suppression leading to infections or bleeding, secondary malignancies, pulmonary fibrosis, and significant hepatic or renal toxicity. Patients should be monitored regularly for blood counts, liver and kidney function, and any signs of respiratory distress.

Leukeran is contraindicated in patients with known hypersensitivity to chlorambucil or other alkylating agents, in those with severe bone‑marrow failure, and in individuals receiving live vaccines. Caution is also advised for pregnant or breastfeeding women and patients with compromised organ function.